13 news items
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
JAZZ
20 Jun 24
head of research and development of Jazz Pharmaceuticals. "We are evaluating the data to better understand the trial results and await the results
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
JAZZ
1 Jun 24
Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "Clinical development
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
JAZZ
30 May 24
treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
JAZZ
29 May 24
treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
JAZZ
29 May 24
and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development
bhjp4qzcib9q1
JAZZ
22 May 24
and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development
29x7l3vc6ataxz6r7g3zfqwvgpwt427qc259o1lk
ABBV
AMGN
CURLF
18 May 24
(OTC:CURLF). Additionally, DEA-authorized studies on cannabis benefits will advance research and development, potentially leading
1lgapu amvo
ABBV
CRBP
CRDL
14 May 24
is expected to accelerate research and development, particularly in medical cannabis, potentially attracting
c8bsn59johg0kjhp4vw55tcdkiu4wm98wztme71oyfkfgessch5tpfr
AMGN
CASI
JAZZ
7 May 24
for the first quarter of 2024, compared with $8.5 million for the same period in 2023. Research and development expense was $6.0 million for the first
2001 w3jrwa9za56pt5x3p5fj19c
JAZZ
1 May 24
-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics
t7os17518
JAZZ
24 Apr 24
, global head of research and development of Jazz Pharmaceuticals. "The abstracts accepted for presentation by Jazz and our partners
fycfh935hrrnyx0h9lvfwghg2ezg1gobknbmtzw
JAZZ
17 Apr 24
treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative
syrme40i54x2qn35o6 y1lqvs
JAZZ
10 Apr 24
Iannone, MD, MSCE, executive vice president and global head of research and development of Jazz Pharmaceuticals. "We remain committed to expanding our
- Prev
- 1
- Next